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Abstract  18 
A new natural proteoglycan from Ganoderma lucidum spore powder (GLSP) was 19 
obtained via solvent extraction and optimized using response surface methodology 20 
(RSM). The differences among the characteristics of the new proteoglycan from 21 
cracked (proteoglycan-C) and uncracked GLSP (proteoglycan-UC) were explored. The 22 
SDS-PAGE results showed the molecular weight of protein contained in proteoglycan-23 
UC (55, 72, 95 kDa) was different to that proteoglycan-C (43, 95 kDa). The differences 24 
of these amino acids (Glu, Arg, Leu and Lys) content and monosaccharides (Fuc, Gal, 25 
Glc, Man and Gal-AC) content between proteoglycan-C and proteoglycan-UC were 26 
determined by HPLC/ ion chromatography. The 2,2’-azino-bis (3-ethylbenzthiazoline-27 
6-sulphonic acid) (ABTS) and 1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical 28 
scavenging activities of proteoglycan-C were higher than that proteoglycan-UC. The 29 
proteoglycan-UC exhibited stronger hypoglycemic and antibacterial effects against E. 30 
coli and S. aureus, and the proteoglycan-C and proteoglycan-UC showed antitumor 31 
effects with potential for therapeutic applications. 32 
 33 
Keywords: proteoglycan; Ganoderma lucidum spore powder; hypoglycemic; 34 
antibacterial; antitumor. 35 
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1. Introduction  37 
In recent years, special attention has been paid to natural products due the prominent 38 
effects and minor side effects of the products in prevention and alleviation of cancer, 39 
hypertension and diabetes [1]. For example, Lentinan, a polysaccharide obtained from 40 
the stipe portion of Lentinus edodes mushroom, revealed anticancer activities against 41 
human colon cancer [2]. In addition, the proteoglycan obtained from Ganoderma 42 
lucidum (G. lucidum) fruiting bodies has demonstrated protective effects on the kidneys 43 
and amelioration of diabetic nephropathy [3]. 44 
G. lucidum is a well-known traditional Chinese medicine herb that has been used to 45 
promote health and longevity for several thousands of years [4]. During the past few 46 
decades, applications of G. lucidum have been explored and include alleviating 47 
symptoms of asthma [5], promoting wound healing [6], as antitumor agents [7] and also 48 
as an oral multidrug [8, 9]. Among the bioactive ingredients, the proteoglycans and 49 
polysaccharides have shown important roles in medicinal potencies [10]. The 50 
proteoglycan is a kind of glycoprotein consisting of a core protein linked to one or more 51 
glycosaminoglycan chains via covalent bonding [11], and shows efficient 52 
hypoglycemic activity in vitro [12] as well as excellent anti-herpetic activities against 53 
type 1 and type 2 herpes simplex virus has been revealed [13]. This suggests the 54 
polysaccharides presence during the extraction of protein is advantageous with regards 55 
to the bioactive effects of the proteoglycan.  56 
  Moreover, the molecular weight, amino acids, monosaccharides contents and the 57 
advantageous bioactive effects (e.g. antioxidant, anticancer, and hyperglycemic 58 
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activities) of proteoglycan should be different between the cracked and uncracked 59 
GLSP. To disclosure that, the optimized extraction parameters for GLSP via RSM was 60 
firstly confirmed. The differences between physicochemical properties, amino acid, and 61 
monosaccharide in cracked GLSP and uncracked GLSP were then explored through 62 
Fourier transform infrared spectroscopy (FTIR), High Performance Liquid 63 
Chromatography (HPLC) and ion chromatography. Subsequently, the antioxidant, 64 
antitumor and antibacterial effects of proteoglycan from cracked and uncracked GLSP 65 
were compared. In consideration of the widespread applications of proteoglycans and 66 
G. lucidum, the results in this study may broaden the source of proteoglycans and 67 
application of GLSP.  68 
 69 
2. Materials and methods 70 
2.1 Materials 71 
  GLSP (cracked and uncracked wall) was offered by TianHe Agricultural Group 72 
(ZheJiang LongQuan, China). Sodium hydroxide (troche), ammonium sulfate (powder), 73 
methanol, absolute ethanol and hydrochloric acid were purchased from Sinopharm 74 
Chemical Reagent Co., Ltd (Shanghai, China). Fetal bovine serum (FBS) was 75 
purchased from Sijiqin (Sijiqin, Hangzhou, zhejiang, China), Dulbecco’s modified 76 
eagle’s medium (DMEM) was purchased from Gibico (Gibco, USA) and deionized 77 
water (DI) were offered by the Millipore Milli-Q Reference ultrapure water purifier 78 
(Millipore, Bedford, USA). Albumin bovine serum (BSA), fluorescein diacetate (FDA), 79 
propidium iodide (PI), AO/EB dye mixture, and Micro Blood Sugar Content Assay Kit 80 
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were offered by Solarbio Life Science (Beijing, China). ABTS, DPPH assay kits, 81 
Coomassie brilliant blue kit, Sodium Dodecyl Sulfate Polyacrylamide Gel 82 
electrophoresis (SDS-PAGE) Gel Quick Preparation Kit were offered by Shanghai 83 
Beyotime biotechnology Co., Ltd (Shanghai, China). Violet red bile agar, baird-parker 84 
agar base, adding egg-yolk tellurite emulsion, nutrient broth, 7.5% sodium chloride 85 
broth were from Qingdao Hope Bio-Technology Co., Ltd (Shandong, China). Universal 86 
indicator paper (pH 1-14, Shanghai SSS reagent Co., Ltd). All chemicals were 87 
analytical grade with no further purification before experimentation.  88 
 89 
2.2 Extraction of proteoglycan  90 
The proteoglycan was obtained using conventional water extraction via a water bath 91 
(DZKW-D-4, Suzhou Jiangdong precise instrument Co., Ltd, Suzhou, China). 92 
Approximately 1g of dried GLSP (uncracked) was dispersed with DI water according 93 
to a predetermined solid-to-liquid ratio, and then kept in the water bath at the 94 
predetermined temperature for predetermined time. The mixture was then centrifuged 95 
at 8000 rpm, at 4 ℃ for 30 min using Centrifuge 5810 R (Eppendorf, Germany), 96 
according the method in previous work [14]. The supernatant was collected and 97 
concentrated using Rotavapor (RE-52A, Shanghai, China) at -0.09 MPa and 55 ℃ to 98 
one-tenth of the volume. Ammonium sulfate was introduced to the concentrated 99 
mixture until saturation. NaOH was introduced to achieve a neutral pH and left to stand 100 
overnight (ca. 20 h). The precipitate was collected via centrifugation and dried at 55°C 101 
for three days in a vacuum over (-0.09MPa, D2F-6020AF, Tianjin, China) for further 102 
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treatment.   103 
The protein content was measured using the Bradford method [15] via a Bio-Rad 104 
protein assay reagent (Bio-Rad, USA). Since proteoglycan is similar to glycoprotein 105 
and there is no single standard for proteoglycan, BSA was used as a standard protein. 106 
Absorbance of BSA was examined at 595 nm using UV spectrophotometer (UV-2600, 107 
Shimadzu, Japan). The standard curve of concentration-absorbance was plotted (in Fig. 108 
S1), and fitting equation is shown in Eq. (1): 109 
 y = 9.1755x + 0.011                                           (1) 110 
where, y was the absorbance, x was the concentration (mg/mL). 111 
Box-behnken design was used to optimize the extraction parameters according to the 112 
results from response surface methodology (RSM) (Design-Expert 8.0.6 Trial, Stat-113 
Ease, Inc. USA). Four three-level independent variables (Table S1) were selected based 114 
on the single factorial assays.  115 
 116 
2.3 Molecular weight determination of protein  117 
  The protein molecular weight was determined using Sodium Dodecyl Sulfate 118 
Polyacrylamide Gel electrophoresis (SDS-PAGE) [16]. Each sample (20 µL, 10 mg/mL) 119 
was determined in SDS-PAGE with a 6% resolving gel and a 5% stacking gel (SDS-120 
PAGE Gel Quick Preparation Kit). The operation was performed at 100 V through 121 
stacking gel followed by 120 V to the end of resolving gel using Power Pac™ Basic 122 
Power Supply (E1100, Bio-RAD, USA). The gels were maintained in boiling water for 123 
5 min before being stained with Coomassie brilliant blue kit. 124 
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 125 
2.4 Fourier transform infrared spectroscopy analysis 126 
The proteoglycans were determined using Fourier transform infrared (FT-IR) 127 
spectroscopy (IR Affinity 1, Shimadzu, Japan). The samples were grounded with KBr 128 
powder and then pressed into pellet using powder compressing machine (FW-4A, 129 
Tianjin TUOPU instrument Co., Ltd, Tianjin, China) under the pressure ~14 MPa for 2 130 
min, and getting the spectrum with 20 scans at a resolution of 4 cm-1 (4000–400 cm-1). 131 
 132 
2.5 Amino acid and monosaccharide composition of proteoglycan 133 
  The amino acid content of the protein was determined using a High Performance 134 
Liquid Chromatography system (HPLC, UitMate 3000, Thermo-Fisher Scientific, 135 
USA), which was equipped with a DAD-3000 (RS) fluorescence detector. The analyte 136 
was separated using an analytical column ZORBAX Eclipse-AAA (4.6 mm×150 mm, 137 
Agilent ZORBAX Eclipse, Agilent Technology, USA). The mobile phase consisted of 138 
Na2HPO4 (pH 7.8) with a concentration of 40 mM and acetonitrile-methanol-DI (45: 139 
45: 10, v/v/v).  140 
  The monosaccharide was detected using an ion chromatograph system (Dionex ICS-141 
5000, Thermo-Fisher Scientific Dionex, USA) combining a chromatographic guard 142 
column (3 mm×50mm, Dionex Carbo PACTM PA20) and anion exchange column (3 143 
mm×250 mm, Dionex Carbo PACTM PA20). The ICS-5000 electrochemical detector 144 
(ED, Thermo-Fisher Scientific Dionex, USA) was equipped with Au working electrode 145 
and Ag/AgCl composite reference electrode.  146 
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 147 
2.6 Free radical scavenging activity assay  148 
The ABTS radical scavenging activity was determined using a total antioxidant 149 
capacity assay kit. In brief, the ABTS radical solution and trolox standard solution with 150 
various concentrations (0.1, 0.2, 0.4, 0.6, 0.8, 1.0 mM) were prepared according to 151 
manufacturer instructions. Peroxidase stock solution was added to a 96-well plate (20 152 
µL/well). DI water was used as blank control, trolox standard solution was added for 153 
the positive control and sample solution was added for the sample group (10 µL/well). 154 
Following that, ABTS radical solution was added (170 µL/well) and the plate was 155 
cultured for 6 minutes at 25°C. The absorbance was measured at 414 nm using Spectra 156 
Max 190 microplate reader (NanoDrop, USA). The antioxidant activity of sample was 157 
shown as Trolox equivalent antioxidant capacity (TEAC) and calculated as Eq. (2), 158 
according to previous works [14, 17] : 159 
TEAC (mM Trolox/ mg protein of sample) = 
+,-+.+. × 012                 (2) 160 
Where, the 𝐴4  is the absorbance of sample; the 𝐴5  is the absorbance of blank 161 
control; the 𝑚	is slope of a plot between antioxidant capacity and mM Trolox; the 𝑋 162 
is mg protein of sample. 163 
The DPPH radical scavenging activity was measured using the previous method of 164 
Yang et al. [18]. Using DI water and ethanol to dissolve proteoglycan and DPPH, to the 165 
final concentration of 100 µg/mL and 0.2 mM, respectively. Mixing 1 mL sample 166 
solution with 2 mL DPPH solution, then incubating for 20 min at 25 ℃ after being 167 
blending. Determining the solution absorbance using microplate reader at 517 nm. 168 
 9 
Using the following Eq. (3) [18] to calculated the DPPH radical scavenging activity of 169 
the sample:  170 
DPPH radical scavenging activity (%) = 1 − 𝐴4 − 𝐴: /𝐴5 ×100%       (3) 171 
Where, the 𝐴4 is the absorbance of sample solution; the 𝐴: is the absorbance of 172 
control, which the DPPH was replaced by ethanol in equal volume; the 𝐴5  is the 173 
absorbance of blank, which the sample solution was replaced by DI water in equal 174 
volume. 175 
 176 
2.7 Hypoglycemic activity assay in vitro 177 
2.7.1 Hypoglycemic effect on normal HepG2 cells  178 
HepG2 (human hepatocellular liver carcinoma) cells (ca. 1.4×105 cells/mL) were 179 
cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin in cell 180 
culture dishes (diameter, Ф= 6 cm) under standard conditions (37 °C, 5% CO2) for 48 181 
h. Then, pipetted cell suspensions into a 96-well plate (100 µL/well) and incubated in 182 
serum-free DMEM at standard conditions for 12 h. Following this, cells for blank 183 
control were incubated in serum-free DMEM, and cells for positive control were 184 
incubated in serum-free DMEM supplemented with metformin (1×10-3mol/L). The 185 
treatment groups were incubated in serum-free DMEM supplemented with various 186 
concentrations of proteoglycan (0.1, 1, 10 mg/mL). After being incubated 24 h, 187 
measuring the glucose content of supernatant of media using Micro Blood Sugar 188 
Content Assay Kit.  189 
 190 
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2.7.2 Hypoglycemic effect on insulin-resistant HepG2 cells   191 
The insulin-resistance model of HepG2 was built according to previous work [19]. 192 
HepG2 cells (ca. 1.4×105 cells/mL) were seeded into a 12-well plate for 24 h in serum-193 
free DMEM. The cells were then treated with serum-free DMEM with insulin (1×10-194 
7mol/L) for 1 h. Subsequently, the cells were incubated in serum-free DMEM with 195 
metformin (1×10-3mol/L) or various concentrations of proteoglycan (1, 5, 10mg/mL) 196 
for 24 h. Finally, the glucose content of supernatant of media was measured by using 197 
UV-Vis.  198 
 199 
2.8 Antitumor activities assay in vitro 200 
2.8.1 Cell viability assay  201 
The antitumor effects of proteoglycan on tumor cell lines were determined using 202 
CCK-8 (cell counting Kit-8 reagent, Dojindo Laboratories, Kumamoto, Japan) assay 203 
[20]. In brief, HeLa cell suspension (ca. 1.4×105 cells/mL) was obtained after being 204 
cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin in cell 205 
culture dishes (Ф = 6 cm) under standard conditions for 48 h. 100 µL cell suspensions 206 
were pipetted into a 96-well plate and incubated at standard conditions for 24 h. For 207 
treatment group, 100 µL each well of proteoglycan solution was added after being 208 
disinfected using UV radiation for 4 h; and 100 µL medium was added to the control. 209 
After being cultured for 24 h, the cells were added 10 µL CCK-8 solution and the 210 
absorbance was measured using the microplate reader at 450nm according to the 211 
instructions of manufacturer. The cell proliferation was calculated by Eq. (4) [21]: 212 
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Cell viability (% of untreated cells) = [(As-Ab)/ (Ac-Ab)] × 100%.           (4) 213 
Where, As, Ac and Ab is the absorbance of treatment group, control group and 214 
blank group, respectively.     215 
 216 
2.8.2 AO/EB staining 217 
  HeLa cells were stained using AO/EB dye mixture. In brief, cell suspension (1.4×105 218 
cells/mL) were seeded into a 6-well plate. After being incubated 24 h for adherence, 219 
the cells were treated with proteoglycan solution with various concentrations (1 or 5 220 
mg/mL) for another 48 h. 20 µL of AO/EB dye mixture (100µg/mL EB and 100 µg/mL 221 
AO into the 6-well plate and left to stand for 30 min at 37°C. The plate was analyzed 222 
using fluorescence microscopy (Olympus, BX61W1-FV1000, Tokyo, Japan). 223 
  224 
2.9 Antibacterial activity assay  225 
The antibacterial effects of proteoglycan on E. coli (NW1014 (8099), Nanjing 226 
Maojie Microbiology Technology Co., Ltd, Jiangsu, China) and S. aureus 227 
(CMCC(B)26003, Shanghai Luwei Microbial SCI. & TECH. Co., Ltd, China) was 228 
studied using the method [22]. Pressing proteoglycan powder (ca. 100 mg) to a disk by 229 
the powder compressing machine. Coating 0.2 mL (1.2×106 CFU/mL) inoculums of E. 230 
coli and S. aureus on violet red bile agar and baird-parker agar base plates adding egg-231 
yolk tellurite emulsion, respectively. Then, put the agar plate (Ф≈3 cm) in biochemical 232 
incubator (SHP-080 Biochemical Incubator, Shanghai Jinghong Laboratory Instrument 233 
Co., Ltd., Shanghai, China) after being placed the proteoglycan disk to the surface of 234 
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agar. The diameter of the inhibition zone was measured after being kept for 24 h at 235 
37°C. 236 
  Meanwhile, 0.01 mL (ca. 1.2×106 CFU/mL) inoculum of E. coli and S. aureus was 237 
added into 100 mL nutrient broth and 7.5% sodium chloride broth respectively, and 238 
then incubated in the biochemical incubator at 37℃ for 24h. After that, using 25 µg/mL 239 
FDA and PI to stain the bacteria for 20 min at 25℃ and was kept away from light. The 240 
fluorescence value was measured using a fluorescence microplate reader (FlexStation 241 
II, NanoDrop, USA), and the fluorescence value was calculated using previous method 242 
[22]. 243 
 244 
2.10 Statistical analysis  245 
  All experiments were performed in triplicate and data is given as mean ± standard 246 
deviation (n=3). Statistical analysis was performed using SPSS software (SPSS 247 
Statistics v18, IBM, UK). The one-way analysis of variance (ANOVA) were revealed 248 
using RSM (Design- Expert 8.0.6 Trial, Stat-Ease, Inc., USA). All the statistical plots 249 
were plotted using Origin software (OriginLab, USA). 250 
  251 
3. Results and discussion 252 
3.1 Optimization of the proteoglycan extraction 253 
   This study of controlling parameters (e.g. time, temperature, extraction times, solid-254 
liquid ratio and pH value) have showed significant effects on the protein yields [23].   255 
Here, we evaluated the proteoglycan extraction efficiency from crude protein content 256 
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of GLSP. Based on the single-factor experiments results (Fig. S2) and feasibility, three-257 
level (-1, 0, 1) four-factor (Table S1) was selected to evaluate the main experimental 258 
effects on yields. The experimental data and results are shown in Table S2. Then, the 259 
regression equation was obtained according to the results of ANOVA:  260 
Y=3.93+0.027×A-0.044×B+0.044×C+0.12×D-0.20×A×B+0.099×A×C+0.079×A×D-261 
0.12×B×C+4.75×B×D×10-3-0.24×C×D-0.63×A2-0.78×B2-0.94×C2-0.88×D2                     262 
(5)  263 
where, Y is the proteoglycan yield (%) in the resultant product probably; A, B, C and 264 
D was the solid-liquid ratio, time, temperature and pH value, respectively.  265 
The RSM results (Fig. 1 & Fig. S3) revealed the interactions among the experimental 266 
parameters. As the results shown (Table S3), the fitting model F-value was 3.23 and p-267 
value was 0.024 (＜0.05), which revealed the quadratic model was significant. The 268 
linear coefficients (A, B, C, D), cross product coefficients (AB, AC, AD, BC, BD, CD) 269 
were found insignificant (p＞0.05), whereas the quadratic coefficients (A2, B2, C2, D2) 270 
exhibited significant effect (p＜0.05). The significant order priority of the four factors 271 
on the result was pH value > time = temperature>solid-liquid ratio, which confirmed 272 
the fact that the little longer extraction time [24] with appropriate temperature [25], and 273 
neutral pH [26] may be improved protein extraction. 274 
After calculations, the predictive maximum protein yield (4.525%) was obtained on 275 
the optimizing parameters: 1:40 (g: mL), 2.93 h, 35.19 ℃ and 10.07 (pH value). For 276 
feasibility, the actual extraction conditions were modified as follows: 1: 40 (g: mL), 3 277 
h, 35 ℃, and 10.00 (pH). The proteoglycan yield obtained under the actual conditions 278 
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was 2.98 % ± 0.06%, which was almost consistent with the predicted yield 3.052%. 279 
These results confirmed the validity of the fitting model and availability of the 280 
optimizing extraction parameters of proteoglycan. 281 
  Then, the difference in physicochemical properties, amino acid, and monosaccharide 282 
content of the proteoglycan from cracked well GLSP (proteoglycan-C) and uncracked 283 
well GLSP (proteoglycan-UC) were explored through FTIR, HPLC and Ion 284 
chromatography. Following that, the antioxidant, antitumor and antibacterial effects of 285 
proteoglycan-C and proteoglycan-UC were compared. 286 
 287 
3.2 FT-IR analysis 288 
FT-IR is frequently used to analyze functional groups of a compound [27-29]. The 289 
FT-IR spectra of proteoglycan-C and proteoglycan-UC are presented in Fig. 2a. The 290 
peaks at 1527 and 1664 cm-1 were due to the presence of amide II and amide I 291 
respectively, which revealed the isolated compound contained protein fractions [30]. 292 
The signals at 2920, 2850, 1478, 1160, 1078 cm-1 were attributed to the presence of 293 
pyranose ring [31]. Moreover, the absorption peaks around 2920, 1620 and 1400cm-1 294 
were the characteristic absorption peaks of polysaccharide [32] due to C-H and –COOH 295 
groups, respectively [24]. The FT-IR results confirmed that the isolated proteoglycan 296 
was a polysaccharide and protein complex. Also, there were no obvious differences in 297 
the functional group between the proteoglycan from cracked and uncracked GLSP; just 298 
a difference in intensity of absorbance peaks (2920cm-1, 2850cm-1). 299 
 300 
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3.3 Determination of protein molecular weight 301 
As the SDS-PAGE results shown (Fig. 2b), three bands showed when the gel was 302 
stained using Coomassie brilliant blue, which revealed the protein was a non-303 
monomeric protein. Comparing with standard protein molecular weight marker (lane 304 
1), the molecular weight of protein in proteoglycan-C (lane 2-4) was 43 and 95 kDa; 305 
and the protein contained in proteoglycan-UC (lane 5-7) possessed molecular weight 306 
as follows: 55, 72 and 95 kDa. The band width of protein with molecular weight 95 307 
kDa of proteoglycan-UC (lanes 5-7) is wider than that of proteoglycan-C (lanes 2-4), 308 
which indicates proteoglycan-UC contains a higher protein content than proteoglycan-309 
C. The protein obtained in this work was consistent with the protein with molecular 310 
range 12 to 150 kDa from Ganoderma boninense [33]. 311 
 312 
3.4 Amino acid content and constitution of polysaccharide   313 
  The amino acid content of proteoglycan was determined using HPLC (Fig. 3a & b). 314 
The content of amino acids (e.g. Asp, Glu, Lys) were calculated (Table S4). The Arg 315 
content of proteoglycan-UC (10.74%) was did not appeared in proteoglycan-C; the 316 
content of Lys in proteoglycan-C (6.32%) was not detected in proteoglycan-UC. The 317 
Asn and Gln were not detected in proteoglycan-C and proteoglycan-UC.  318 
The monosaccharide contained in proteoglycan was determined using Ion 319 
chromatograph system. The results (Fig. 3c & d) revealed the presence of several kinds 320 
of monosaccharide (e.g. Fuc, Gal, Gal-AC) in resulting proteoglycan. According to the 321 
spectra of standard curves of monosaccharides (Fig. S4 b-f), the contents of these 322 
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monosaccharides were measured (Table S5). The Ara and Gal-AC content of 323 
proteoglycan-UC was 0.125 µg/mg and n.a, respectively, but did not appear in 324 
proteoglycan-C. Besides, the Glc and Man contents of proteoglycan-UC (524.281, 325 
6.386 µg/mg, respectively) were more than twice of that proteoglycan-C (247.959, 326 
2.667 µg/mg, respectively). While the Fuc and Gal content of proteoglycan-UC was 327 
1.186 µg/mg and 7.421µg/mg respectively, higher content was found in proteoglycan-328 
C (3.308 µg/mg and 13.320 µg/mg, respectively). The Xyl, Fru, Rib and Glc-AC were 329 
not detected in proteoglycan-C and proteoglycan-UC. The results confirmed that the 330 
effect of GLSP (cracked or uncracked) on the monosaccharide content was significant. 331 
Differences in amino acid and monosaccharide content of proteoglycan between 332 
cracked and uncracked wall GLSP may be attributed to two main causes. The first is 333 
oxidation reactions which occur in cracked wall GLSP. Secondly, Maillard reaction 334 
between monosaccharides and amino acids influence ion chromatography detection. 335 
The latter can also occur (and impact) during ion chromatography experimental 336 
conditions [34].  337 
 338 
3.5 Free radical scavenging activity 339 
The scavenging effect of ABTS was expressed as Trolox equivalent antioxidant 340 
capacity (TEAC), as shown in Fig. 4. The ABTS scavenging activity of proteoglycan-341 
C and proteoglycan-UC (1 mg/mL) was 73.3±6.7% and 47.2±5.9%, respectively while 342 
the DPPH scavenging activity of proteoglycan-C and proteoglycan-UC (1 mg/mL) was 343 
90.6±8.5% and 72.6±3.7%, respectively.  344 
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The scavenging effects of ABTS and DPPH radicals confirmed the antioxidant 345 
activities of the resulting proteoglycan. The radical scavenging value of proteoglycan-346 
C was higher than that of proteoglycan-UC, which was the same for both ABTS and 347 
DPPH test. The differences among these amino acid contents might be the key causes 348 
responsible for the antioxidant activities differences of the proteoglycans as the 349 
peptides contained in the amino acids (His, Phe and Pro) (Tables S4 & S5) have shown 350 
antioxidant activity [35]. 351 
 352 
3.6 Hypoglycemic activity in vitro 353 
  Metformin is used for the treatment of type 2 diabetes, and is a commercially 354 
available hypoglycemic drug [36]. Numerous studies have used this drug to 355 
demonstrate hypoglycemic activity, typically as a positive control when examining 356 
hypoglycemic effects between various treatment groups. Therefore, metformin was 357 
selected to compare hypoglycemic activity of proteoglycan in the current work. The 358 
glucose concentration of the supernatant of media after being cultured for 24 h indicated 359 
the capacity of glucose consumption of HepG2 cell. The hypoglycemic potency of 360 
proteoglycan on normal HepG2 cells is shown in Fig. 5a. The glucose concentration in 361 
the proteoglycan treatment (10 mg/mL) was comparable with the metformin treatment 362 
group (10-3 mol/L). Differences in hypoglycemic effect on normal HepG2 cells between 363 
treatment and control groups was not significant. This may be due to normal HepG2 364 
cells being insensitive to proteoglycan at the given concentration, since significant 365 
differences were observed for insulin resistance type HepG2 cells Furthermore, the 366 
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glucose concentration in treatment of proteoglycan-C was lower than proteoglycan-UC 367 
at each concentration (0.1, 1, 10 mg/mL). This revealed the hypoglycemic effect of 368 
proteoglycan-C was stronger than proteoglycan-UC, and indicates proteoglycan 369 
(concentration of 10 mg/mL) exhibits a similar hypoglycemic effect as metformin at a 370 
concentration of 10-3 mol/L on normal HeG2 cells. 371 
  The hypoglycemic effect of proteoglycan on insulin-induced insulin resistance type 372 
HepG2 cells, which used to imitate T2DM patients [12] is shown in Fig. 5b. The 373 
glucose concentration in insulin treatment group (10.91 ± 0.56 mM) was comparable 374 
with that of control (10.92±0.18 mM), indicating that the insulin-induced insulin 375 
resistance type HepG2 cells were constructed successfully. Comparing with control, the 376 
hypoglycemic effect of resulting proteoglycan-C and proteoglycan-UC on insulin 377 
resistance type HepG2 cells were obvious, for the P-＜0.05 (p- value was 0.03 and 0.02, 378 
respectively). Furthermore, the glucose concentration treated by proteoglycan-C was 379 
little lower than that of proteoglycan-UC. 380 
  The mechanism under the hypoglycemic effect of the proteoglycan is most likely an 381 
interaction between proteoglycan and protein tyrosine phosphatase 1B (PTP1B), which 382 
was inhibited via interactions between the carboxyl groups of Asp and Glu and Tyr20, 383 
Arg24 and Arg254 active sites of PTP1B [37]. Thus, the differences of Asp and Glu 384 
content (Table S4) in proteoglycan-C and proteoglycan-UC were the major causes for 385 
the difference in hypoglycemic activity.  386 
 387 
3.7 Antitumor and antibacterial activities 388 
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3.7.1 Antitumor activity  389 
  HeLa cells are human cervical cancer cells, which has been used to confirm 390 
antitumor activity in vitro [16, 38]. As shown in Fig. 6a, the HeLa cell viability 391 
decreased as treatment dose and time increases. When HeLa cells were treated with 0.5 392 
or 1.0 mg/mL of proteoglycan-C for 12 h, the cell viability was 95.2 ± 1.5% and 72.5 393 
± 1.9%, respectively, and decreased further (to 69.9 ± 2.6% and 62.3 ± 0.9%) at the 394 
treatment of 48 h. The result of proteoglycan-UC on the cell viability was 90.3 ± 0.9% 395 
and 78.2 ± 5.3% for 0.5 or 1.0 mg/mL for 12 h, respectively, and then decreased to 396 
69.1±1.0% and 58.2 ± 0.9% when treated for 48 h, respectively. 397 
  The antitumor effect can be visualized via AO/EB dual staining results (Fig. 6). The 398 
blank control (Fig. 6b) presented bright green with slight orange fluorescence, 399 
indicating most vital cells. At the treatment of proteoglycan-C or proteoglycan-UC (1.0 400 
mg/mL) (Fig. 6b1 & c1), the green fluorescence was weaker and orange fluorescence 401 
was brighter, while little less orange fluorescence showed with lower concentration (0.5 402 
mg/mL) treatment (Fig. 6b2 & c2). This indicates the number of viable cells was less 403 
than that of the control and the number of necrotic cells had increased; consistent with 404 
previously reported studies [39]. The results confirmed the antitumor activity of 405 
proteoglycan, which probably due to the polysaccharide fraction in proteoglycan can 406 
stimulate the immune system [40] or suppress the cell growth by inhibiting the activity 407 
of Akt and transcription factors AP-1 and nuclear factor-kappa B (NF-κB) [41] .  408 
 409 
3.7.2 Antibacterial activity 410 
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  The antibacterial properties of the resulting proteoglycan were tested against E. coli 411 
(G-) and S. aureus (G+), which were quantified using FDA/PI staining method [22]. 412 
Compared to control, the proportion of viable cells for E. coli decreased to 89.6 ± 9.9% 413 
and the necrotic cells proportion increased to 112.5 ± 9.1% (Fig. 7a) at the treatment of 414 
proteoglycan-C (1mg/mL). The proportion of viable and necrotic cells of was 93.6 ± 415 
9.2% and 107.5 ± 3.9% respectively when E. coli was treated with proteoglycan-UC 416 
(1mg/mL). For S. aureus (Fig. 7b), at the treatment of proteoglycan-C (1 mg/mL), the 417 
proportion of viable and necrotic cells was 90.8 ± 8.7% and 124.9 ± 6.5% respectively. 418 
The same treatment of proteoglycan-UC induced the proportion of viable and necrotic 419 
cells was 97.5 ± 5.4% and 108.4 ± 7.1% respectively. Thus, these results indicate the 420 
antibacterial activities against E. coli and S. aureus of proteoglycan-UC were stronger 421 
than proteoglycan-C. 422 
  The antibacterial properties can be visualized using disk diffusion method [42]. Figs. 423 
7 c1-d2 presents a clear inhibition zone with agar plates coated with E. coli and S. 424 
aureus. The diameter of inhibition zone for S. aureus is larger than that for E. coli (Table 425 
1). The difference in activity is attributed to the bacterial cell type. S. aureus is Gram-426 
positive bacteria and restricting entry of nutrients into cells leads to death. E. coli is 427 
Gram-negative bacteria and an increase in cell permeability results in death [43]. This 428 
is the same case for both proteoglycan-C and proteoglycan-UC, which was consistent 429 
with previous works [44]. The probable mechanism was that binding of polysaccharides 430 
induces cell membrane destruction, which led to apoptosis ultimately [45]. Besides, the 431 
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difference of Gal, Man, and Glu content (Table S4 & 5) between proteoglycan-UC and 432 
proteoglycan-C differed the antibacterial properties probably [44]. 433 
 434 
4. Conclusion  435 
  In summary, the proteoglycan from GLSP was obtained using conventional water 436 
extraction. The extraction parameters were optimized through RSM results. The results 437 
revealed that the proteoglycan obtained from cracked and uncracked GLSP differed its 438 
characteristics with respect to molecular weight, amino acid content, monosaccharide 439 
content and antibacterial activity. The proteoglycan-C (from cracked GLSP) possessed 440 
smaller molecular weight, higher content amino acid of Lys and monosaccharide of Gal 441 
comparing with that proteoglycan-UC (from uncracked GLSP). Moreover, the 442 
proteoglycan-UC contained higher content amino acids of Arg, Glc, monosaccharide 443 
of Man, and revealed stronger antibacterial effects against E. coli and S. aureus and 444 
stronger hypoglycemic effect in vitro than that of proteoglycan-C. Meanwhile, the 445 
proteoglycan-C exhibited stronger scavenging effects against ABTS and DPPH radicals. 446 
The antitumor effects against HeLa cells of proteoglycan-C were similar to that of 447 
proteoglycan-UC. Overall, the obtained results regarding antioxidant, hypoglycemic, 448 
antitumor and antibacterial activity revealed that the resulting proteoglycan from GLSP 449 
is useful as a functional additive as well as a potential candidate for a therapeutic agent. 450 
 451 
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Figure and Table legends 595 
 596 
Table 1. Inhibition zone obtained using agar plates method against E. coli and S. aureus 597 
 598 
Fig. 1. Contour plots (2D) for response surface plots results: a-f corresponding to temperature and 599 
time, pH and temperature, pH and time, time and solid-to-liquid ratio, pH and solid-to-liquid-ratio, 600 
temperature and solid-to-liquid ratio, respectively. 601 
 602 
Fig. 2. FT-IR spectroscopy of proteoglycan (a) and SDS-PAGE of crude protein contained in 603 
proteoglycan (b): lane 1, molecular weight markers; lane 2-4, proteoglycan-C in triplicate; lane 5-604 
7, proteoglycan-UC in triplicate. 605 
 606 
Fig. 3. Amino acids content of proteoglycan-UC (a) and proteoglycan-C (b); monosaccharides 607 
content of proteoglycan-UC (c) and proteoglycan-C (d). 608 
 609 
Fig. 4. The antioxidant effects of proteoglycan-C and proteoglycan-UC. 610 
 611 
Fig. 5. The hypoglycemic capacity against normal HepG2 cells (a) and insulin resistance type 612 
HepG2 cells (b) of proteoglycan. 613 
 614 
Fig. 6. Effects of proteoglycan on HeLa cell viability using CCK-8 assay (a); Fluorescent images of 615 
HeLa cells morphology of blank control group (b) and treated with proteoglycan-C of 1.0 mg/mL 616 
(b1), 0.5 mg/mL (b2) and proteoglycan-UC of 1.0 mg/mL (c1), 0.5 mg/mL (c2). 617 
 618 
Fig. 7. Effects of proteoglycan on HeLa cell viability using CCK-8 assay (a); and on proliferation 619 
of E. coli (a) and S. aureus (b); inhibition zone results of proteoglycan-UC (c1, d1) and 620 
proteoglycan-C (c2, d2) against E. coli (c1, c2) and S. aureus (d1, d2). 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 27 
 630 
Table 631 
Table 1 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
 646 
 647 
 648 
 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 Inhibition zone diameter (Ф, mm) 
 Proteoglycan-UC Proteoglycan-C 
E. coli 
S. aureus 
20.1 20.8 
25.2 27.2 
 28 
 667 
Figures  668 
 669 
  670 
 671 
Fig. 1 672 
 673 
 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
 682 
 683 
 684 
 685 
 686 
 29 
   687 
Fig. 2 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
 698 
 699 
 700 
 701 
 702 
 703 
 704 
 705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
 714 
 715 
 716 
 717 
 718 
 719 
 720 
 30 
 721 
722 
 723 
Fig. 3.  724 
 725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
 733 
 734 
 31 
 735 
 Fig. 4 736 
 737 
 738 
 739 
Fig. 5 740 
 741 
 742 
 743 
 744 
 32 
 745 
 746 
  747 
Fig. 6 748 
 749 
 750 
 751 
 752 
 753 
 33 
 754 
 755 
 756 
 757 
 758 
Fig. 7 759 
 760 
 761 
 762 
 763 
 764 
